WHO Seeks Clarification on Coldrif Exports
The World Health Organization (WHO) has asked India to clarify whether the contaminated Coldrif cough syrup, linked to the deaths of children in Madhya Pradesh, was exported to other countries. The move raises the possibility of a global alert if international shipments are confirmed.
Contamination and Deaths Reported
Recent investigations revealed that batches of Coldrif contained diethylene glycol (DEG) at nearly 500 times the permissible limit. The syrup, manufactured by Sresan Pharmaceuticals in Tamil Nadu, has been blamed for multiple child deaths. The incident has renewed concerns over gaps in India’s pharmaceutical quality checks.
Regulatory Action in India
India’s drug regulator flagged widespread lapses across multiple pharma firms, including failures in testing raw materials and final products. Following the findings, Coldrif sales have been banned nationwide, and Sresan’s manufacturing unit has been sealed. Police have also filed manslaughter charges against those linked to the production.
Global Repercussions
If Coldrif was exported, WHO could issue a Global Medical Products Alert, which may affect India’s standing as a major supplier of medicines worldwide. The government is under pressure to assure international markets about corrective steps and tighter oversight in pharmaceutical exports.
